Forecasting & Franchise Strategy
Strengthen your portfolio by making more informed decisions and prepare for the impact of new research discoveries.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
-
Patient Engagement
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Public Health and Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
Advance your patient engagement strategy
Discover new patient engagement possibilities with IQVIA insights, expertise, and technology-driven solutions.
Patient Engagement OverviewPatient Engagement Quick Links
- Commercial Engagement Solutions
- Commercial Patient Engagement Suite
- eCOA
- Clinical Outcome Assessment (COA) instrument library
- Linguistic Validation
- Patient-Centered Endpoints
- Engagement Services (US)
- Association Management
- Recruitment
- Journey Analytics
- Patient Finder
- Disease insights
- Disease Registries
- Treatment satisfaction
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience powered by Apple
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions powered by Apple
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBlog
Advancement of Treatment with Biologics in CNS Diseases
IQVIA Forecast Link
Aug 25, 2023
Use of biologics in the central nervous system (CNS) field is growing rapidly, with sales of $19 billion in 2018 increasing to a forecast $49 billion in 2032 according to IQVIA’s Forecast Link. A number of diseases are behind this growth, including migraine, myasthenia gravis and muscular dystrophy as seen in the graph below.
Source: IQVIA Forecast Link, July 2023
In comparison, growth of non-biologics in the CNS field, which includes small molecules, has increased from $105 billion in 2018 to $140 billion in 2032. Non-biologics contribute the vast majority of the market share, but new biologics are providing growth.
Source: IQVIA Forecast Link, July 2023
Migraine has seen significant growth in the use of biologics in the last 5 years, with four Calcitonin gene-related peptide (CGRP)-antagonists currently approved for treatment. These biologics offer the benefit of preventing migraine episodes and reducing the number of headaches patients experience per month. Prior to this, therapies for migraine prevention were not migraine specific and were associated with low adherence due to poor tolerability and insufficient efficacy1.
Biologics have also transformed multiple sclerosis treatment options with the introduction of multiple CD20-positive B-cell depleting monoclonal antibodies. An issue that biologics development in CNS diseases face is the ability of drugs to cross the blood brain barrier because monoclonal antibodies are large molecules. Therefore, large doses are given to ensure a sufficient dose reaches the brain and this also increases the risk of serious side effects2. Disease progression in relapsing-remitting MS may be due to lack of penetration of the blood brain barrier by these monoclonal antibodies3.
Whilst some CNS diseases have seen major progression in recent years and show strong sales forecasts, others such as Alzheimer’s disease lag behind. With an aging population, there is significant need for a therapeutic that can slow, reverse or stop development of the disease, which is devastating for patients and families and the burden on healthcare systems and communities is substantial. The unmet need and large patient population means there are potentially extremely high profits to be made but achieving this is proving difficult. Drug developers have faced failure after failure with pipeline monoclonal antibodies. However, in recent years two biologics have received approval and although the path has not been smooth, these approvals open the gateway to future growth and forecasted sales are positive in the disease.
Drug development in Alzheimer’s disease has been a frustratingly slow process, but patients, families and experts are cautiously optimistic that as the understanding of both the disease and how to gain regulatory approval grows, so will treatment options.
For more information on brand and country specific forecasts in any disease, please contact IQVIA and request a demonstration of Forecast Link, an online tool containing 5 years historical and 10 years of forecast data in 73 countries, for 10,000 drugs and over 600 diseases. Forecast Link provides unrivalled breadth of coverage and is updated quarterly. To find out more, please visit Forecast Link: Disease.
References
- https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-020-01211-5
- https://pubmed.ncbi.nlm.nih.gov/33756057/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605202/
- https://pubmed.ncbi.nlm.nih.gov/35516416/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697739/